Antileishmanial Activity of Tamoxifen by Targeting Sphingolipid Metabolism: A Review

IF 3.1 Q2 PHARMACOLOGY & PHARMACY Clinical Pharmacology : Advances and Applications Pub Date : 2022-02-01 DOI:10.2147/CPAA.S344268

Kaleab Alemayehu Zewdie, Haftom Gebregergs Hailu, M. A. Ayza, B. Tesfaye

{"title":"Antileishmanial Activity of Tamoxifen by Targeting Sphingolipid Metabolism: A Review","authors":"Kaleab Alemayehu Zewdie, Haftom Gebregergs Hailu, M. A. Ayza, B. Tesfaye","doi":"10.2147/CPAA.S344268","DOIUrl":null,"url":null,"abstract":"Abstract Leishmaniasis is a widespread group of neglected parasitic diseases caused by protozoa of the genus Leishmania. Around 2 million new cases are reported each year and around 12 million people are at risk of being infected. Although various therapies have been used to treat leishmaniasis, they have been associated with increased cytotoxicity and drug resistance problems. Hence, the present review was intended to show the potential of tamoxifen as an alternative option for the treatment of leishmaniasis. Tamoxifen is a known selective estrogen receptor modulator and has been widely used for the treatment of early-stage breast cancer. Various experimental and clinical studies revealed that it has an antileishmanial effect by decreasing parasitic burden, with low cost and few side effects. The antileishmanial action of tamoxifen has been related to its potential effect on sphingolipid metabolism. Besides, it affects mitochondrial function by inducing alterations in the plasma membrane potential. However, further detailed studies are required to show the ultimate effects on health outcomes.","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"14 1","pages":"11 - 17"},"PeriodicalIF":3.1000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology : Advances and Applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CPAA.S344268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

Abstract

Abstract Leishmaniasis is a widespread group of neglected parasitic diseases caused by protozoa of the genus Leishmania. Around 2 million new cases are reported each year and around 12 million people are at risk of being infected. Although various therapies have been used to treat leishmaniasis, they have been associated with increased cytotoxicity and drug resistance problems. Hence, the present review was intended to show the potential of tamoxifen as an alternative option for the treatment of leishmaniasis. Tamoxifen is a known selective estrogen receptor modulator and has been widely used for the treatment of early-stage breast cancer. Various experimental and clinical studies revealed that it has an antileishmanial effect by decreasing parasitic burden, with low cost and few side effects. The antileishmanial action of tamoxifen has been related to its potential effect on sphingolipid metabolism. Besides, it affects mitochondrial function by inducing alterations in the plasma membrane potential. However, further detailed studies are required to show the ultimate effects on health outcomes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

他莫昔芬针对鞘脂代谢的抗利什曼动物活性研究进展

摘要利什曼病是由利什曼原虫属原生动物引起的一组广泛分布的被忽视的寄生虫病。每年报告约200万例新病例，约1200万人面临感染风险。尽管各种疗法已被用于治疗利什曼病，但它们与细胞毒性增加和耐药性问题有关。因此，本综述旨在显示他莫昔芬作为治疗利什曼病的替代选择的潜力。三苯氧胺是一种已知的选择性雌激素受体调节剂，已广泛用于治疗早期癌症。各种实验和临床研究表明，它具有降低寄生虫负担的抗利什曼原虫作用，成本低，副作用少。三苯氧胺的抗利什曼原虫作用与其对鞘脂代谢的潜在影响有关。此外，它通过诱导质膜电位的改变来影响线粒体功能。然而，还需要进一步的详细研究来显示对健康结果的最终影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊